FIELD: pharmaceutics.
SUBSTANCE: invention relates to the use of a guanine derivative of formula (I) and its pharmaceutically acceptable salts as inhibitors of human poly(ADP-ribose)polymerase.
EFFECT: effective inhibition of PARP activity, capable of having a cytoprotective effect and suppressing the proliferation of tumor cells.
1 cl, 3 dwg, 2 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
AGENT FOR POLY(ADP-RIBOSO) POLYMERASE INHIBITION | 2012 |
|
RU2522915C2 |
N-[3-OXO-LUPANO-28-YL]-PIPERIDINE - AGENT HAVING ANTI-TUMOUR, ANTI-METASTATIC, ANTI-INFLAMMATORY AND CYTOPROTECTIVE ACTIVITY | 2011 |
|
RU2466136C1 |
INHIBITOR OF ATP-DEPENDENT REVERSE CELL TRANSPORTERS AND METHOD FOR ITS PRODUCTION | 2016 |
|
RU2641304C1 |
THERAPEUTIC COMBINATIONS CONTAINING INHIBITOR OF POLY(ADP-RIBOSE)POLYMERASE | 2005 |
|
RU2361592C2 |
DERIVATIVES OF O-ALKYLGUANINE AND PHARMACEUTICAL COMPOSITION | 1994 |
|
RU2154646C2 |
METHODS FOR TREATING PANCREATIC CANCER | 2017 |
|
RU2768479C2 |
PARP-INHIBITING COMPOUNDS AND COMPOSITIONS, AND METHODS FOR USING THEM | 2008 |
|
RU2485122C2 |
TRICYCLIC PARP INHIBITORS | 2004 |
|
RU2404183C2 |
N-(2-(2-(2-AZIDOETHOXY)ETHOXY)ETHYL)-4,6-DI(AZIRIDIN-1-YL)-1,3,5-TRIAZIN-2-AMINE, HAVING CYTOTOXIC ACTION | 2023 |
|
RU2825828C1 |
ANTITUMOR COMPOSITION OF DOXORUBICIN WITH ATP INHIBITOR-DEPENDENT REVERSE CELL TRANSPORTER | 2018 |
|
RU2680834C1 |
Authors
Dates
2022-11-10—Published
2022-01-12—Filed